基因多态性检测对指导缺血性脑卒中患者阿司匹林和氯吡格雷应用的临床意义  

Clinical significance of gene polymorphism detection in guiding the application of aspirin and clopidogrel in the treatment of ischemic stroke

作　　者：张楠楠[1] 李佳慧 李小杰 孙玉洁 刘业松[1] 赵萌 赵仕琪 ZHANG Nannan;LI Jiahui;LI Xiaojie(Department of Neurology,Kailuan General Hospital,Hebei,Tangshan 063000,China)

机构地区：[1]开滦总医院神经内科,河北省唐山市063000

出　　处：《河北医药》2023年第13期1988-1990,1994,共4页Hebei Medical Journal

摘　　要：目的探讨基因多态性检测对指导阿司匹林、氯吡格雷和治疗缺血性脑卒中患者的临床意义及预后。方法本研究选取2019年10月至2020年10月收治的缺血性脑卒中患者200例,随机分为试验组和对照组,每组100例。试验组通过基因多态性检测后推荐的药物治疗,对照组选择目前指南中推荐的用药方法,于3、6、12个月后各观察1次,比较2组终点事件的发生率。结果试验组12个月内发生终点事件发生率为0、1.0%、3.0%明显低于对照组的12.0%、14.0%、15.0%,差异有统计学意义(P<0.05)。结论基因多态性检测在指导缺血性脑卒中患者临床用药,尤其是选择阿司匹林、氯吡格雷及预后具有重要意义。Objective To explore the clinical significance and prognosis of genetic polymorphism detection in guiding the application of aspirin and clopidogrel in the treatment of ischemic stroke.Methods Patients with ischemic stroke admitted to Kailuan General Hospital from October 2019 to October 2020 were randomly divided into test group(n=100)and control group(n=100).Patients in the test group were given recommended drugs after performing gene polymorphism detection,and those in the control group were given recommended drugs based on current guidelines.After 3,6 and 12 months of treatment,the incidence of endpoint events was compared between the two groups.Results The incidence of endpoint events at 3(0 vs 12.0%),6(1.0%vs 14.0%)and 12 months(3.0%vs 15.0%)of treatment in the test group was significantly lower than that in the control group(all P<0.05).Conclusion The detection of gene polymorphism is of great significance in guiding the clinical application of aspirin and clopidogrel in patients with ischemic stroke and their prognosis.

关 键 词：基因多态性 阿司匹林 氯吡格雷 缺血性脑卒中 

分 类 号：R743.31[医药卫生—神经病学与精神病学]